July 19, 2010, 7:30 a.m. EDT · Recommend · Post:

Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Non-Small Cell Lung Cancer
Telomerase Inhibitor as Maintenance Therapy Targets Cancer Stem Cells

MENLO PARK, Calif., Jul 19, 2010 (BUSINESS WIRE) -- Geron Corporation /quotes/comstock/15*!gern/quotes/nls/gern (GERN 4.70, +0.13, +2.85%) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

"Initiating our first randomized Phase 2 clinical trial of imetelstat is a major milestone for Geron's Oncology program," said Stephen M. Kelsey, M.D., Geron's executive vice president and chief medical officer, oncology. "We are now poised to apply what we learned clinically from our Phase 1 program as well as leverage recent preclinical results showing imetelstat's activity against a broad range of cancer stem cell types, including those from NSCLC."